Deerfield Management Company L.P. Series C Invests $1.02 Million in Hologic, Inc. (NASDAQ:HOLX)

Deerfield Management Company L.P. Series C purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 13,734 shares of the medical equipment provider’s stock, valued at approximately $1,020,000.

A number of other institutional investors have also recently added to or reduced their stakes in HOLX. D.A. Davidson & CO. acquired a new position in shares of Hologic during the 4th quarter worth about $204,000. Corient Private Wealth LLC raised its holdings in shares of Hologic by 251.1% during the fourth quarter. Corient Private Wealth LLC now owns 51,106 shares of the medical equipment provider’s stock valued at $3,652,000 after acquiring an additional 36,550 shares during the last quarter. SageView Advisory Group LLC purchased a new position in shares of Hologic in the fourth quarter valued at approximately $289,000. Parallel Advisors LLC boosted its stake in shares of Hologic by 11.5% in the fourth quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock worth $131,000 after acquiring an additional 189 shares during the last quarter. Finally, TD Asset Management Inc increased its position in shares of Hologic by 2.8% during the fourth quarter. TD Asset Management Inc now owns 1,897,705 shares of the medical equipment provider’s stock worth $135,591,000 after purchasing an additional 52,243 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HOLX. Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Tuesday, September 17th. Evercore ISI raised their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 30th. StockNews.com cut Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. lifted their price objective on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and an average price target of $87.60.

Insider Transactions at Hologic

In related news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares in the company, valued at $310,415.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now directly owns 45,472 shares in the company, valued at $3,615,024. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock worth $1,469,973 over the last ninety days. Company insiders own 1.75% of the company’s stock.

Hologic Trading Down 1.7 %

Shares of HOLX stock opened at $79.86 on Thursday. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67. The firm has a market cap of $18.55 billion, a PE ratio of 40.75, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. The company has a 50-day moving average of $80.98 and a two-hundred day moving average of $77.22. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the company posted $0.93 EPS. On average, analysts predict that Hologic, Inc. will post 4.09 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.